Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS5019651 A
Publication typeGrant
Application numberUS 07/540,997
Publication dateMay 28, 1991
Filing dateJun 20, 1990
Priority dateJun 20, 1990
Fee statusPaid
Also published asCA2044923A1, CA2044923C, DE69113325D1, DE69113325T2, EP0462663A1, EP0462663B1
Publication number07540997, 540997, US 5019651 A, US 5019651A, US-A-5019651, US5019651 A, US5019651A
InventorsGerard R. Kieczykowski
Original AssigneeMerck & Co., Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US 5019651 A
Abstract
An improved process is described for the preparation of 4-amino-1-hydroxybutylidene-1,1-bisophosphonic acid (ABP) or salts thereof which comprises:
(a) reacting 4-aminobutyric acid with a mixture of phosphorous acid and PCl3 in the presence of methanesulfonic acid;
(b) contacting the mixture from Step (a) with an aqueous hydrolysis mixture, wherein the pH is maintained in the range of 4 to 10 during the contacting; and
(c) recovering said 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof.
Images(4)
Previous page
Next page
Claims(10)
What is claimed is:
1. A process for the preparation of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof which comprises:
(a) reacting 4-aminobutyric acid with a mixture of phosphorous acid and PCl3 in the presence of methanesulfonic acid;
(b) contacting the resulting mixture from Step (a) with an aqueous hydrolysis mixture, wherein the pH is maintained the range at 4 to 10 during the contacting; and
(c) recovering said 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof.
2. The process of claim 1 wherein the pH is maintained in Step (b) in the range of 6-8.
3. The process of claim 1 further comprising step (b-2), heating said resulting mixture from Step (b) in the range of 50 C. to the boiling point.
4. The process of claim 1 wherein said Step (b) is conducted at a temperature of from 0 C. to 90 C.
5. The process of claim 4 wherein said temperature is 0-20 C.
6. The process of claim 1 wherein said aqueous hydrolysis mixture in Step (b) is a phosphate buffer.
7. The process of claim 6 wherein said buffer comprises monosodium dihydrogen phosphate and disodium monohydrogen phosphate.
8. The process of claim 1 wherein 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt trihydrate is recovered.
9. The process of claim 1 wherein 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid is recovered.
10. A process for the preparation of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof which comprises:
(a) reacting 4-aminobutyric acid with a mixture of phosphorous acid and PCl3 in the presence of methanesulfonic acid at a temperature of about 65 C.;
(b) contacting the resulting mixture from Step (a) with an aqueous phosphate buffer at a temperature in the range of 0-20 C., and maintaining the pH between 6-8 during the contacting;
(b-2) heating the resulting mixture from Step (b) at the boiling point; and
(c) recovering said 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof.
Description
BACKGROUND OF THE INVENTION

This invention relates to an improved process for making 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof, where the end product is obtained in pure form and high yield, and which avoids the use of a strongly-acidic hydrolysis medium.

It is known according to U.S. Pat. No. 4,407,761 to Henkel Kommanditgesellschaft to prepare 4-amino-1-hydroxy-butylidene-1,1-bisphosphonic acid by bisphosponating an aminocarboxylic acid with phosphonating reactants and then quenching the reaction mixture by addition of a strong non-oxidizing acid, preferably concentrated hydrochloric acid, with heating, to hydrolyze the formed phosphorous intermediates to final product. However, problems result from this reaction because the bisphosphonation reaction mixture does not remain homogeneous and local solidification occurs. This solidification causes variable yields, which in part results from the exothermic nature of the reaction due to the development of "hot spots". Moreover, to make the sodium salt, utilizing the prior art processes, requires isolation of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid and an additional step to convert this to the monosodium salt. Further, the use of concentrated hydrochloric acid in the quench, whose fumes present an environmental problem, is also required.

Furthermore, U.S. Pat. No. 4,922,007 to G. R. Kieczykowski, et al. (assigned to Merck & Co., Inc.) discloses the use of methanesulfonic acid to overcome the non-homogeneity and solidification problems associated with the bisphosphonation phase, but utilizes a non-pH controlled water quench which leads to the presence of a strongly acidic and corrosive hydrolysis mixture which requires the use of expensive glass reaction vessels with their inherent pressure limitations.

The present invention solves these problems by the use of methanesulfonic acid to allow the bisphosphonation reaction to remain fluid and homogeneous, and using a pH-controlled aqueous quench in the range of 4 to 10, followed by hydrolysis, which eliminates the need for concentrated hydrochloric acid in the quench. The present invention also eliminates the need to handle a corrosive acidic product hydrolysis mixture, such that stainless steel hydrolysis equipment rather than glass equipment can be utilized. Glass equipment has inherent pressure limitations not possessed by stainless steel. This is a big advantage in the instant process since it has been found that, by conducting the hydrolysis under pressure, the hydrolysis rate can be significantly increased.

It has been found that, in the quench, a pH above 10 leads to lower yields due to formed intermediates which resist hydrolysis, and a pH below 4 leads to much longer hydrolysis times. Further, it has been found that ABP is unstable at a pH above 8, thus limiting the reaction times and hydrolysis times at higher pHs.

SUMMARY OF THE INVENTION

By this invention, there is provided a process for the preparation of 4-amino-1-hydroxy-butylidene-1,1-bisphosphonic acid or salts thereof which comprises:

(a) reacting 4-aminobutyric acid with a mixture of phosphorous acid and PCl3 in the presence of methanesulfonic acid;

(b) contacting the resulting mixture from Step (a) with an aqueous hydrolysis mixture, wherein the pH is maintained in the range of 4 to 10 during the contacting; and

(c) recovering said 4-amino-1-hydroxybutyl-idene-1,1-bisphosphonic acid or salts thereof.

The reaction can further be conducted by controlling the pH during the aqueous quench in a narrow range, i.e. 6-8, maintaining the temperature between 0-20 C., and then heating the hydrolysis mixture at 50 C. - reflux, or under pressure for a sufficient time to insure complete hydrolysis to the titled product.

DETAILED DESCRIPTION OF THE INVENTION

The present invention process provides pure crystallized 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid, or salts thereof, which can surprisingly be obtained in high yields. The invention involves the bisphosphonation of an aminoalkane carboxylic acid with phosphonating reactants in the presence of methanesulfonic acid, quenching the reaction mixture with an aqueous hydrolysis mixture, maintaining the pH at 4 to 10, hydrolyzing the phosphorus intermediates, formed in the quench procedure, and recovering 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof. The compound can be crystallized directly from the reaction mixture in about 90% yield after the pH controlled hydrolysis, and pH adjustment to about 4.3 with no further purification necessary.

The aminoalkane carboxylic acids which can be used is 4-aminobutyric acid. The bisphosphonation reaction generally takes place at temperatures of from 45 to 125 C., preferably at about 65 C.

Generally 1 to 3, preferably 2.0 moles of H3 PO3 and generally 1 to 5.0, preferably 4.0 mols of PCl3 are used per mol of aminocarboxylic acid. Smaller amounts of 4-aminobutyric acid can be used which limits the formation of ABP dimers and decreases the necessary hydrolysis times. If desired, inert organic diluents, which do not solubilize the reaction product, particularly helped or chlorinated hydrocarbons, such as chlorobenzene, tetrachloroethane, tetrachloroethylene and trichloroethylene can be used in the reaction with methanesulfonic acid.

Following the reaction to form the product, the reaction is quenched, i.e. drowned into an aqueous hydrolysis mixture. The conditions of the quench are such that pH is controlled in the range of pH 4 to 10, and preferably the pH is controlled in a narrow pH region, i.e. 6-8. By controlling the pH in this manner, it has been found that the yield of ABP can be maximized.

The aqueous hydrolysis mixture can contain basic or acidic materials or buffering agents.

Representative examples include sodium, potassium and lithium hydroxides, carbonates, bicarbonates, dihydrogen phosphates, hydrogen phosphates, borates, oxalates, tartrates, phthalates, phosphorous acid salts, and the like, and mixtures thereof.

Preferred is where the hydrolysis mixture is a buffered solution, preferrably a phosphate or bicarbonate buffered solution in the range pH 6-8.

The pH of the resulting quench mixture can also be controlled during the hydrolysis drown by the simultaneous addition of a basic reagent, e.g. sodium hydroxide.

The temperature of the quench is carried out in the range of 0-90 C., and preferably 0-20 C.

The required time of the quench drowning procedure will vary according to the volumes used.

Following the pH-controlled, temperature-controlled quench, the resulting mixture is stirred and heated in the temperature range of 50 C. to reflux and preferably at the reflux temperature of about 105-110 C. to complete and insure complete hydrolysis.

The volume ratio of the reaction mixture from the phosphonation Step (a) to the volume of the aqueous hydrolysis mixture in the quench Step (b) is about 1 to 5.

Alternatively, the hydrolysis mixture can be partially concentrated to about half the original volume, by distillation at atmospheric or reduced pressure, diluted with water to about the original volume and then refluxed. This procedure substantially reduces the hydrolysis time.

As a further alternative, the hydrolysis mixture can be heated at 110-165 C. in a closed vessel under pressure. This also substantially reduces the hydrolysis times.

It should be noted that a pH above about 7-8, the product ABP starts to undergo degradation with resultant yield loss, and thus preferably the desired hydrolysis workup procedure should be carried out in the pH range 6-8.

The reaction is schematically represented as follows: ##STR1##

4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt trihydrate described here is useful as a pharmaceutical composition and for the treatment or prevention of diseases involving bone resorption. Such diseases as hypercalcemia of malignancy, Paget's disease, and osteoporosis are advantageously treated with 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt trihydrate made according to the process of the present invention.

Other pharmaceutically acceptable salts, such as for example the calcium, potassium salts, can be prepared according to the processes of the present invention and are included within the scope thereof.

The following examples are illustrative of the practice of the invention without being limiting in any way.

EXAMPLE 1 Non-pH-Controlled Hydrolysis Preparation of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt trihydrate

Bisphosphonation Reaction Phase

A 250 mL flask was fitted with a mechanical stirrer, a thermocouple, an addition funnel and a reflux condenser through which is circulated -20 C. brine. The system was connected to a caustic scrubber which places a back pressure of 0.5-1 psig on the system. The system was flushed with nitrogen and charged with 20 g (0.19 mol) of aminobutyric acid, 80 mL of methanesulfonic acid, and 24 g (0.29 mol) of phosphorous acid. For larger scale operations, the methanesulfonic acid can be charged first, followed by the 4-aminobutyric acid and phosphorous acid. Upon mixing, the heat of neutralization and solution increased the reaction temperature to 75 C. The suspension was aged for 15 minutes at 70-75 C. resulting in a clear colorless solution. The solution was cooled to 35 C. and phosphorus trichloride (PCl3), 40 mL (0.46 mol) was added cautiously over 20 minutes. The reaction was then heated to 65 C. and aged at that temperature for 20 hours. The reaction should not be allowed to get much above 65 C. The reaction becomes self-heating above 85 C. and under adiabatic conditions the temperature will increase steadily. At about 150 degrees an exotherm accompanied by a large pressure release occurs. It is therefore recommended that the reaction be immediately quenched into cold water if the temperature reaches 85 C.

Quench; Hydrolysis

The reaction was then cooled to 25 C. and added to 200 mL of deionized water over 5 minutes. The flask was rinsed with an additional 100 mL of water and the combined strongly-acid solution (pH less than zero) aged at 95-100 C. for 5 hours. The reaction was cooled to 20 C. and maintained at 20-25 C. while the pH was adjusted to 4.3 with ca. 80 mL of 50% NaOH. The resulting white suspension was then cooled to 0-5 C. and aged for 1 hour. The pH was readjusted to 4.3 if necessary and the suspension aged at 0-5 C. for an additional 2 hours. The product was collected by filtration, then washed with 250 mL of cold (0-5 C.) water and 100 mL of 95% EtOH. The yield after air drying at 40 C. to constant weight was 56.4 g (90%).

EXAMPLE 2 Use of pH-Controlled Hydrolysis

4-aminobutyric acid: 20 g

methanesulfonic acid: 160 ml

phosphorous acid: 32 g

phosphorus trichloride: 80 ml

Bisphosphonation Reaction Phase

The above reagents were mixed and heated at 65 C. for 5 hours analogously according to the procedure of Example 1.

Quench; Hydrolysis

The reaction mixture was quenched over 35 minutes by adding dropwise to a solution of 10 g Na2 HPO4 in one liter of water, at pH=7.0. The pH of the quench was maintained between 6.0 and 7.0 by simultaneously adding 25% sodium hydroxide and maintained below 25 C. by cooling with ice. Once the quench was complete, the pH was adjusted to 7.0 and the solution concentrated to 1080 ml by atmospheric distillation (100-104 C.) over 3 hours. At this point, the reaction was subdivided into 2 parts, A and B.

A, being 630 ml, was concentrated further to 450 ml after adjusting the pH to 4.3. The solution was aged overnight at ambient temperature during which time the product crystallized. The suspension was aged at 0 C. for 2 hours then filtered, washed with 100 ml of cold water, 100 ml of 1:1 water/ethanol, and 100 ml of 100% ethanol and dried, yielding 20.5 g (56% yield).

B, being 450 ml, was treated by refluxing an additional 16 hours before adjusting the pH to 4.3 and concentrating to 300 ml. The product was isolated as above providing 16.5 g. (63% yield) of ABP.

This Example illustrates that the above bisphosphonation reaction, in conjunction with a buffered quench, minimized the ABP dimers and phosphonates which are more difficult to hydrolyze, thus reducing the required hydrolysis times.

EXAMPLE 3

4-aminobutyric acid: 60 g

methanesulfonic acid: 240 ml

phosphorous acid: 48 g

phosphorus trichloride: 120 ml

Bisphosphonation

The reaction was run analogously using the procedure described in Example 1 (65 C. overnight) with the above quantity of reagents. The total reaction volume was 430 ml. The reaction was subdivided into aliquots prior to quenching.

Quench; Hydrolysis

Aliquots were quenched into 100 ml of water while simultaneously adding 20% sodium hydroxide to maintain a pH of 6-10. The pH was adjusted to different values between 4-10 and the reaction refluxed for an appropriate amount of time to produce and isolate product (see below). The pH was then adjusted to 7 and the solution filtered. The pH was then adjusted to 4.3 and the solution aged overnight during which time the product crystallized. The suspension was then aged at 0 C. for 2 hours and filtered. The cake was washed with water then ethanol and dried.

______________________________________Aliquot  pH        Time Refluxed1                          Yield______________________________________50 m1    11        1      day    9.6 g  (44%)46 ml    10        2      days   11.4 g (56%)20 ml    9         2      days   5.0 g  (54%)23 ml    8         6      days   6.8 g  (66%)21 ml    7         10     days   6.6 g  (72%)21 ml    7         10     days   7.2 g  (78%)221 ml    7         5      days   7.0 g  (75%)321 ml    7         42     hrs.4                            2.4 g  (65%)21 ml    6         11     days   6.8 g  (74%)  ml     5                days5                            g      ( %)  ml     4                days5                            g      ( %)  ml     3                days5                            g      ( %)______________________________________ 1 Temperature between 105-110 C. at 1 atmosphere. 2 Used an equal volume of ethanol in the crystallization. 3 Partially concentrated by atmospheric distillation to about half the volume, diluted with an equal volume of water and then refluxed. 4 After quenching, refluxed at 140 C. in a closed pressure vessel. 5 After 12 days, the hydrolysis mixture was analyzed by phosphorus NMR. The pH = 5 and pH = 4 reactions indicated incomplete hydrolysis mixtures. The pH = 3 reaction indicated incomplete hydrolysis mixture and significantly longer hydrolysis times projected for its completion.

This Example illustrates that the product can be quenched and hydrolyzed under neutral and basic conditions in good yield, but that at the higher pH values, the yields are lower due to competing degradation of the product.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3848420 *Mar 16, 1973Nov 19, 1974Gullick Dobson LtdMine roof supports
US4054598 *Jul 16, 1976Oct 18, 1977Henkel & Cie Gmbh1-Hydroxy-3-amino-alkane-1,1-diphosphonic acids and salts
US4064164 *Jul 16, 1976Dec 20, 1977Henkel Kommanditgesellschaft Auf Aktien1,3-Di-amino-alkane-1,1-diphosphonic acids and salts
US4100167 *May 9, 1977Jul 11, 1978Nalco Chemical CompanyProduction of 1-aminoalkane-1, 1-diphosphonic acids using phosphorous acid and nitriles in a non-aqueous system
US4157364 *Feb 8, 1978Jun 5, 1979Buckman Laboratories, Inc.Process for preparing dimethylaminomethylenebis(phosphonic acid)
US4267108 *Sep 21, 1978May 12, 1981Henkel Kommanditgesellschaft Auf AktienHydroxyalkane diphosphonic acids
US4304734 *Oct 16, 1980Dec 8, 1981Vysoka Skola Chemicko-Technologicka6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof
US4327039 *Oct 1, 1980Apr 27, 1982Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa)Process for the production of 3-amino-1-hydroxypropane-1,1-diphosphonic acid
US4407761 *Apr 16, 1981Oct 4, 1983Henkel Kommanditgesellschaft Auf AktienProcess for the production of ω-amino-1-hydroxyalkylidene-1,1-bisphosphonic acid
US4418019 *Dec 7, 1981Nov 29, 1983Hoechst AktiengesellschaftProcess for the manufacture of 1-aminoalkane-1,1-diphosphonic acids
US4578376 *Dec 3, 1984Mar 25, 1986Istituto Gentili S.P.A.Pharmaceutical compositions for the treatment of osteopathias
US4621077 *Jun 8, 1984Nov 4, 1986Istituto Gentili S.P.A.Pharmacologically active biphosphonates, process for the preparation thereof and pharmaceutical compositions therefrom
US4624947 *Sep 16, 1985Nov 25, 1986Henkel Kommanditgesellschaft Auf Aktien4-dimethylamino-1-hydroxybutane-1,1-diphosphonic acid, salts thereof, and processes therefor
US4705651 *Oct 11, 1985Nov 10, 1987Istituto Gentili S.P.A.Process for the preparation of diphosphonic acids
US4711880 *Sep 8, 1986Dec 8, 1987Ciba-Geigy CorporationCrystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
US4814326 *Dec 1, 1987Mar 21, 1989Istituto Gentili S.P.A.Pharmaceutical compositions based on diphosphonates for the treatment of arthrosis and osteoarthritis
US4922007 *Jun 9, 1989May 1, 1990Merck & Co., Inc.Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
Non-Patent Citations
Reference
1 *Bulletin of Academy of Sciences of the U.S.S.R., Band 27, No. 2, Teil 2 (1978).
2 *Lancet, Apr. 14, 1979, pp. 803 805.
3Lancet, Apr. 14, 1979, pp. 803-805.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US5270365 *Dec 17, 1991Dec 14, 1993Merck & Co., Inc.Prevention and treatment of periodontal disease with alendronate
US5442102 *Apr 3, 1992Aug 15, 1995Boehringer Mannheim Italia S.P.A.Gem-diphosphonic acid nitrosocarbamoyl derivatives, a process for the preparation thereof and pharmaceutical compositions containing them
US5446187 *Apr 3, 1992Aug 29, 1995Boehringer Mannheim Italia S.P.A.Aminoacyl derivatives of gem-diphosphonic acids, a process for the preparation thereof and pharmaceutical compositions containing them
US5449819 *Jun 6, 1994Sep 12, 1995Merck & Co., Inc.Process for removing waste pox, alendronate and its by products
US5462932 *May 17, 1994Oct 31, 1995Merck & Co., Inc.Oral liquid alendronate formulations
US5510517 *Aug 4, 1994Apr 23, 1996Merck & Co., Inc.Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
US5589691 *Jun 6, 1994Dec 31, 1996Merck & Co., Inc.Process for recovery and recycle of methanesulfonic acid and phosphorous acid
US5648491 *Aug 24, 1994Jul 15, 1997Merck & Co., Inc.Process for producing n-amino-1-hydroxy-alkyl-idene-1,1-bisphosphonic acids
US5780455 *Aug 24, 1994Jul 14, 1998Merck & Co., Inc.Intravenous alendronate formulations
US5792885 *Aug 13, 1997Aug 11, 1998Dong Kook Pharmaceutical Co., Ltd.Preparation of 3-amino-1-hydroxypropane-1, 1-diphosphonic acid
US5843924 *Mar 2, 1998Dec 1, 1998Merck & Co., Inc.Intravenous alendronate formulations
US5849726 *Jun 3, 1996Dec 15, 1998Merck & Co., Inc.Anhydrous alendronate monosodium salt formulations
US5908959 *Feb 6, 1998Jun 1, 1999Apotex Inc.Process for the production of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5914099 *May 8, 1996Jun 22, 1999Merck & Co., Inc.Prevention of tooth loss by the administration of alendronate or its salts
US5914323 *May 5, 1998Jun 22, 1999Merck & Co., Inc.Intravenous alendronate formulations
US6008207 *Aug 13, 1998Dec 28, 1999Merck & Co., Inc.Anhydrous alendronate monosodium salt formulations
US6143919 *May 18, 1999Nov 7, 20003M Innovative Properties CompanyPolymerizable acidic compounds and methods of preparation
US6281381Aug 27, 1999Aug 28, 2001Teva Pharmaceutical Industries Ltd.Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US6315566May 18, 1999Nov 13, 20013M Innovative Properties CompanyDental materials
US6331533Nov 9, 1999Dec 18, 2001Merck & Co., Inc.Method for inhibiting dental resorptive lesions
US6399592Jun 23, 1997Jun 4, 2002Merck & Co., Inc.Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
US6414151Apr 27, 1999Jul 2, 2002The Procter & Gamble CompanyProcess for making 1,3-disubstituted-4-oxocyclic ureas
US6420568Apr 27, 1999Jul 16, 2002The Procter & Gamble CompanyProcess for making 1,3-disubstituted-4-oxocyclic ureas
US6432931Jun 21, 1999Aug 13, 2002Merck & Co., Inc.Compositions and methods for inhibiting bone resorption
US6476006Jan 26, 2001Nov 5, 2002Teva Pharmaceutical Industries, Ltd.Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6558702Apr 13, 2001May 6, 2003Alkermes Controlled Therapeutics, Inc.Method of modifying the release profile of sustained release compositions
US6573401Jul 17, 2000Jun 3, 2003Medichem, S.A.Process for producing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid and its trihydrated monosodium salt
US6677320Jan 11, 2001Jan 13, 2004Hoffmann-La Roches Inc.Parenteral bisphosphonate composition with improved local tolerance
US6696601Jul 3, 2001Feb 24, 2004Teva Pharmaceutical Industries, Ltd.Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US6699850Dec 21, 2001Mar 2, 2004Merck & Co., Inc.Compositions and methods for inhibiting bone resorption
US6878846Jun 21, 2002Apr 12, 2005Rhodia Consumer Specialties Ltd.Solvent systems
US6963008Dec 31, 2003Nov 8, 2005Teva Pharmaceutical Industries Ltd.Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US7009071 *May 8, 2002Mar 7, 2006Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S.Process for the preparation of 4-amino-1-hydroxybutylidene-1, 1-biphosphonic acid
US7074432Jan 16, 2004Jul 11, 2006Alkermes Controlled Therapeutics, Inc.Method of modifying the release profile of sustained release compositions
US7192938Nov 29, 2004Mar 20, 2007Hoffmann-La Roche Inc.Method of treatment using bisphosphonic acid
US7332603Nov 25, 2002Feb 19, 2008Chemi S.P.A.Preparation of biphosphonic acids and salts thereof
US7361761Sep 19, 2006Apr 22, 2008Orchid Chemicals & Pharmaceuticals Ltd.Process for the preparation of bisphosphonic acid
US7410957May 6, 2003Aug 12, 2008Hoffmann-La Roche Inc.Method of treatment using bisphosphonic acid
US7411087Aug 10, 2004Aug 12, 2008Sun Pharmaceutical Industries LimitedProcess for preparation of bisphosphonic acid compounds
US7414151Dec 27, 2006Aug 19, 2008Ipca Laboratories Ltd.Process for manufacture of 4-amino-hydroxybutylidene-1, 1-bisphosphonic acid and its salts
US7439385 *Jul 24, 2006Oct 21, 2008Alembic LimitedProcess for the preparation of biphosphonic derivatives
US7449499Aug 11, 2004Nov 11, 20083M Innovative Properties CompanySelf-etching dental compositions and methods
US7452924Aug 11, 2004Nov 18, 20083M Espe AgSelf-etching emulsion dental compositions and methods
US7528280Jan 18, 2007May 5, 2009Aurobindo Pharma Ltd.Process for the preparation of biphosphonic acids
US7612229Jan 27, 2004Nov 3, 2009Richter Gedeon Vegyeszeti Gyar Rt.Industrial process for the synthesis of 2-substituted 1-(hydroxy-ethylidene)-1,1-bisphosfi- conic acids of high purity and the salts thereof
US7632098Aug 11, 2004Dec 15, 20093M Innovative Properties CompanySelf-adhesive dental compositions and methods
US7699605Oct 9, 2008Apr 20, 20103M Espe AgSelf-etching emulsion dental compositions and methods
US7718634Jun 16, 2008May 18, 2010Hoffman-La Roche Inc.Method of treatment using bisphosphonic acid
US7872144Jun 13, 2005Jan 18, 2011Jubilant Organosys LimitedProcess for producing biphosphonic acids and forms thereof
US7923028Apr 12, 2011Hoffman-La Roche Inc.High dose oral formulation of bisphosphonate and a process for making thereof
US8003820Oct 18, 2006Aug 23, 2011Dr. Reddy's Laboratories LimitedProcess for preparing bisphosphonic acids
US8026388Sep 27, 2011Synthon BvProcess for making 1-hydroxyalkylidene-1,1-biphosphonic acids
US8029286Sep 19, 2008Oct 4, 20113M Innovative Properties CompanySelf-etching dental compositions and methods
US8158153Mar 17, 2006Apr 17, 2012Alkermes Pharma Ireland LimitedNanoparticulate bisphosphonate compositions
US8404144Nov 21, 2008Mar 26, 20133M Innovative Properties CompanyCompositions including polymerizable bisphosphonic acids and methods
US8465284Jul 7, 2005Jun 18, 20133M Innovative Properties CompanyDental methods, compositions, and kits including acid-sensitive dyes
US8722760Aug 9, 2005May 13, 20143M Innovative Properties CompanySelf-adhesive compositions including a plurality of acidic compounds
US8779135Oct 4, 2010Jul 15, 2014Straitmark Holding AgMethod for the manufacture of aminohydroxy diphosphonic acids
US20030013918 *Jun 21, 2002Jan 16, 2003Rhodia Consumer Specialties LimitedSolvent systems
US20030078211 *Mar 25, 2002Apr 24, 2003Merck & Co., Inc.Compositions and methods for inhibiting bone resorption
US20030225039 *May 6, 2003Dec 4, 2003Frieder BaussMethod of treatment using bisphosphonic acid
US20030236192 *Mar 25, 2003Dec 25, 2003Alkermes Controlled Therapeutics, Inc.Method of modifying the release profile of sustained release compositions
US20040121007 *Aug 12, 2003Jun 24, 2004Hans-G KaestleHigh dose oral formulation of bisphosphonate and a process for making thereof
US20040138180 *Oct 3, 2003Jul 15, 2004Barr Laboratories, Inc.Bisphosphonate composition and process for the preparation thereof
US20040147488 *Jan 16, 2004Jul 29, 2004Alkermes Controlled Therapeutics, Inc.Method of modifying the release profile of sustained release compositions
US20040152916 *May 8, 2002Aug 5, 2004Kadir DabakProcess for the preparation of 4-amino-1-hydroxybutylidene-1,1-biphosphonic acid
US20040158098 *Dec 31, 2003Aug 12, 2004Nina FinkelsteinNovel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US20040206932 *Dec 5, 2003Oct 21, 2004Abuelyaman Ahmed S.Compositions including polymerizable bisphosphonic acids and methods
US20050065117 *Sep 16, 2004Mar 24, 2005Pfizer IncPharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate
US20050113343 *Oct 13, 2004May 26, 2005Pliva - Research And Development Ltd.Solid-state form of alendronate sodium and preparation thereof
US20050148521 *Jul 23, 2004Jul 7, 2005Yissum Research Development Company Of The Hebrew UniversityAnti-cancer combination and use thereof
US20050175965 *Aug 11, 2004Aug 11, 2005Craig Bradley D.Self-etching dental compositions and methods
US20050175966 *Aug 11, 2004Aug 11, 2005Afshin FalsafiSelf-adhesive dental compositions and methods
US20050176844 *Aug 11, 2004Aug 11, 2005Aasen Steven M.Self-etching emulsion dental compositions and methods
US20050181043 *Feb 12, 2004Aug 18, 2005Indranil NandiAlendronate salt tablet compositions
US20050288509 *Nov 25, 2002Dec 29, 2005Lorenzo De FerraPreparation of biphosphonic acids and salts thereof
US20060122395 *Jan 27, 2004Jun 8, 2006Jozsef NeuIndustrial process for the synthesis of 2-substituted 1-(hydroxy-ethylidene)-1,1-bisphosfi- conic acids of high purity and the salts thereof
US20060128960 *Feb 8, 2006Jun 15, 2006Rami Lidor-HadasNovel process for making bisphosphonic acids using diluents other than halogenated hydrocarbons
US20060154899 *Aug 25, 2003Jul 13, 2006Yongxin HanOxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
US20060166938 *Mar 27, 2006Jul 27, 2006Frieder BaussMethod of treatment using bisphosphonic acid
US20060210639 *Mar 17, 2006Sep 21, 2006Elan Pharma International LimitedNanoparticulate bisphosphonate compositions
US20060258625 *Jul 24, 2006Nov 16, 2006Alembic LimitedProcess for the preparation of biphosphonic derivatives
US20060258726 *Jun 3, 2003Nov 16, 2006Xavier Billot1,5-Disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
US20060269602 *May 8, 2006Nov 30, 2006Dasch James RMethod of modifying the release profile of sustained release compositions
US20060270721 *Aug 2, 2006Nov 30, 2006Yongxin HanEP4 receptor agonist, compositions and methods thereof
US20060293524 *Aug 10, 2004Dec 28, 2006Patel Vijaykumar MProcess for preparation of bisphosphonic acid compounds
US20070066569 *Sep 19, 2006Mar 22, 2007Orchid Chemicals & Pharmaceuticals Ltd.Process for the preparation of bisphosphonic acid
US20070142636 *Oct 18, 2006Jun 21, 2007Mandava Venkata Naga BrahmeswaProcess for preparing bisphosphonic acids
US20070149486 *Dec 27, 2006Jun 28, 2007Ipca Laboratories Ltd.Process for manufacture of 4-amino-hydroxybutylidene-1,1-bisphosphonic acid and its salts
US20070166237 *Mar 20, 2007Jul 19, 2007The Procter & Gamble CompanyMethod for the treatment of bone disorders
US20070215275 *May 18, 2007Sep 20, 2007Nitto Denko CorporationProtective film
US20070248927 *Aug 9, 2005Oct 25, 2007Thomas LuchterhandtSelf-Adhesive Compositions Including a Plurality of Acidic Compouns
US20080249069 *Jun 16, 2008Oct 9, 2008Frieder BaussMethod of treatment using bisphosphonic acid
US20080299519 *Jul 7, 2005Dec 4, 2008Craig Bradley DDental Methods, Compositions, and Kits Including Acid-Sensitive Dyes
US20090011388 *Sep 19, 2008Jan 8, 20093M Innovative Properties CompanySelf-etching dental compositions and methods
US20090035728 *Oct 9, 2008Feb 5, 20093M Innovative Properties CompanySelf-etching emulsion dental compositions and methods
US20090075239 *Nov 21, 2008Mar 19, 20093M Innovative Properties CompanyCompositions including polymerizable bisphosphonic acids and methods
US20090170815 *Dec 23, 2008Jul 2, 2009Roxane Laboratories Incorporated.Alendronate oral liquid formulations
US20090209763 *Feb 10, 2009Aug 20, 2009Rami Lidor-HadasNovel Process For Making Bisphosphonic Acids Using Diluents Other Than Halogenated Hydrocarbons
US20090312551 *Jun 13, 2005Dec 17, 2009Satish Chandra PandeyProcess for producing biphosphonic acids and forms thereof
US20100010258 *Jul 10, 2009Jan 14, 2010Jiri BartlProcess for making 1-hydroxyalkylidene-1,1-biphosphonic acids
US20100015578 *Dec 12, 2007Jan 21, 2010Afshin FalsafiMethods of using a dental composition having an acidic component and a photobleachable dye
US20100130746 *Nov 27, 2009May 27, 2010Martin KasProcess for Making Zoledronic Acid
US20100197637 *Apr 8, 2010Aug 5, 2010Frieder BaussMethod of Treatment Using Bisphosphonic Acid
EP1364956A1 *May 21, 2002Nov 26, 2003Rhodia Consumer Specialties LimitedSolvent systems for the production of bisphosphonates
EP1702924A2 *Aug 27, 1999Sep 20, 2006Teva Pharmaceutical Industries LtdNovel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
EP1803727A1Dec 19, 2006Jul 4, 2007IPCA Laboratories LimitedImproved process for manufacture of 4-amino-hydroxybutylidene-1,1-bisphosphonic acid and its salts
EP2269584A1Apr 14, 2005Jan 5, 2011Warner Chilcott Company, LLCEnteric solid oral dosage form of a bisphosphonate containing a chelating agent
EP2283825A1Apr 14, 2005Feb 16, 2011Warner Chilcott Company, LLCEnteric solid oral dosage form of a bisphosphonate containing a chelating agent
EP2308563A1May 2, 2003Apr 13, 2011F. Hoffmann-La Roche AGRisedronic acid for treatment and prevention of bone resorption diseases
EP2783687A1Feb 24, 2006Oct 1, 2014Merck Sharp & Dohme Corp.Composition for inhibition of cathepsin K
EP2851105A1May 2, 2003Mar 25, 2015F. Hoffmann-La Roche AGBisphosphonic acids for treatment and prevention of osteoporosis
WO1995006052A1 *Aug 24, 1994Mar 2, 1995Merck & Co., Inc.Process for producing n-amino-1-hydroxy-alkyl-idene-1,1-bisphosphonic acids
WO1995033755A1 *Jun 2, 1995Dec 14, 1995Merck & Co., Inc.PROCESS FOR REMOVING WASTE POx, ALENDRONATE AND ITS BY-PRODUCTS
WO1995033756A1 *Jun 2, 1995Dec 14, 1995Merck & Co., Inc.Process for recovery and recycle of methanesulfonic acid and phosphorous acid
WO1996033199A1 *Apr 16, 1996Oct 24, 1996Merck & Co., Inc.Process for making 1-hydroxybisphosphonates
WO1996039107A1Jun 3, 1996Dec 12, 1996Merck & Co., Inc.Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
WO1998014196A1 *Oct 2, 1997Apr 9, 1998Merck & Co., Inc.Liquid alendronate formulations
WO2000012517A1 *Aug 27, 1999Mar 9, 2000Teva Pharmaceutical Industries Ltd.Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
WO2005019161A1Aug 19, 2004Mar 3, 2005Merck Frosst Canada Ltd.Cathepsin cysteine protease inhibitors
WO2005044831A2Aug 10, 2004May 19, 2005Sun Pharmaceutical Industries LimitedA process for preparation of bisphosphonic acid compounds
WO2005120477A2Jun 3, 2005Dec 22, 2005Merck & Co., Inc.N- (2-benzyl) -2-phenylbutanamides as androgen receptor modulators
WO2007132478A2 *May 9, 2007Nov 22, 2007Ind-Swift Laboratories LimitedProcess for the preparation of pure risedronic acid or salts
WO2010143193A1Jun 10, 2010Dec 16, 2010Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.Targeted liposomes comprising n-containing bisphosphonates and uses thereof
WO2011023280A1Jul 29, 2010Mar 3, 2011Synthon B.V.Process for making 1-hydroxyalkylidene-1,1-biphosphonic acids
WO2011039378A1Oct 4, 2010Apr 7, 2011Straitmark Holding AgMethod for the manufacture of aminohydroxy diphosphonic acids
WO2013008240A2Jul 12, 2012Jan 17, 2013Yissum Research Development Company Of The Hebrew University Ofjerusalem Ltd.Liposomes co-encapsulating a bisphosphonate and an amphipathic agent
WO2015054089A1Oct 6, 2014Apr 16, 2015Merck Sharp & Dohme Corp.Cathepsin cysteine protease inhibitors
WO2015159153A1Apr 16, 2015Oct 22, 2015Wrocławskie Centrum Badań Eit+ Sp. Z O.O.Novel bisphosphonates and their use
WO2015181676A1May 18, 2015Dec 3, 2015Pfizer Inc.Carbonitrile derivatives as selective androgen receptor modulators
Classifications
U.S. Classification562/13
International ClassificationC07F9/38
Cooperative ClassificationC07F9/3873
European ClassificationC07F9/38A6U
Legal Events
DateCodeEventDescription
Mar 18, 1991ASAssignment
Owner name: MERCK & CO., INC., LINCOLN AVE., RAHWAY, NJ A CORP
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:KIECZYKOWSKI, GERARD R.;REEL/FRAME:005630/0677
Effective date: 19900620
Oct 5, 1994FPAYFee payment
Year of fee payment: 4
Oct 16, 1998FPAYFee payment
Year of fee payment: 8
Sep 24, 2002FPAYFee payment
Year of fee payment: 12
Jan 27, 2010ASAssignment
Owner name: MERCK SHARP & DOHME CORP.,NEW JERSEY
Free format text: CHANGE OF NAME;ASSIGNOR:MERCK & CO., INC.;REEL/FRAME:023852/0595
Effective date: 20091102
Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY
Free format text: CHANGE OF NAME;ASSIGNOR:MERCK & CO., INC.;REEL/FRAME:023852/0595
Effective date: 20091102